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cu.2012.Abstract A new series of 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-substitutedphenyl)aceta-
mides (2–15a–c) were designed and synthesized in order to evaluate their anticonvulsant activity.
The structure of the synthesized compounds was conﬁrmed by elemental analysis and spectral data
(IR, 1H NMR and Mass). The data obtained from biological screening revealed that; compounds 9c
and 8c showed the highest anticonvulsant activities in experimental mice.
ª 2012 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Epilepsy, a common chronic neurological disorder that is char-
acterized by recurrent unprovoked seizures, inﬂicts more than
60 million people worldwide according to epidemiological
studies.1
Every year approximately 250,000 new cases are added to
this ﬁgure. It is roughly estimated that 28–30% of patients01225704.
.com (K. El-Adl).
Faculty of Pharmacy, Cairo
g by Elsevier
, Cairo University. Production and
11.003are resistant to the available medical therapies.2 It is important
to emphasize that epileptic patients should use the anticonvul-
sant drugs continuously for years. Hence the chronic toxicity
of such a long term is of particular importance.3 The goal of
an anticonvulsant is to suppress the rapid and excessive ﬁring
of neurons that start a seizure.4
Despite the development of several new anticonvulsants, the
treatment of epilepsy remains still inadequate, and the patients
suffer from a lot of speciﬁc problems like neurotoxicity, depres-
sion and other CNS related diseases. Moreover many antiepi-
leptic drugs have serious side effects and lifelong medication
may be required. Therefore, it is essential to search for newer
and potent chemical entities for the treatment of epilepsy.5
Drugs in each therapeutic classiﬁcation frequently show
some common basic chemical structure, it is the hope of the
chemist that, by the addition of various side chains or a com-
bination of side chains or by somewhat altering the basichosting by Elsevier B.V.Open access under CC BY-NC-ND license.
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102 M.-K. Ibrahim et al.structure itself, he will ﬁnd compounds better suited for thera-
peutic use.
Quinoxaline derivatives have received much attention in re-
cent years due to their biological signiﬁcance and pharmaceu-
tical applications.6–8 Many quinoxaline derivatives have been
reported to possess anticonvulsant activity.9,10 Some quinoxa-
line derivatives showed a highly signiﬁcant effect as an anti-
convulsant in comparing to diazepam as a reference drug.9,11
Many currently prescribed antiepileptic drugs (AEDs) act via
voltage-gated sodium channels, voltage-gated calcium chan-
nels, voltage-gated potassium channels, activation of c-amino-
butyric acid (GABA) receptor, or by inhibition of the
glutamate receptor.12,13 Glutamate receptors are classiﬁed into
two major subtypes, N-methyl-D-aspartate (NMDA) and a-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
(AMPA) receptors. AMPA receptor antagonists may have
greater potential clinical utility than do the NMDA antago-
nists14 due to the fact that the latter may produce schizophre-
nia-like symptoms.15
Extensive studies have been conducted on quinoxaline
derivatives to possess central nervous system (CNS) depressant
action with potent (AMPA) receptor antagonist activity, which
in some cases inhibit AMPA-induced lethal convulsions in
mice.10,11,16–18 Several members of this family were found to
exhibit moderate to signiﬁcant anticonvulsant activity in com-
paring to Phenobarbital as the standard drug.17,18 Further-
more, Compound I (Figure 1) was reported as a potent
AMPA receptor antagonist.16
On the other hand it has been reported that a lot of com-
pounds containing acid, ester, amide, acid hydrazide,17–21 oxa-
diazole, pyrazole,20,21 semicarbazide, thiosemicarbazide20 and/
or arylidene17–21 moieties possess good anticonvulsant activity.
Stimulated by the successful applications of quinoxaline
derivatives as anticonvulsant agents, our objective was to syn-
thesize novel derivatives of quinoxaline endowed with the pre-N
H
H
N O
O
O2N
O2N
Figure 1 Compound I potent AMPA receptor antagonist.viously mentioned moieties, hoping that the hybrid of these
pharmacophoric features would produce enhanced anticonvul-
sant activity and compare the difference in the pharmacologi-
cal effect.
Therefore a new series of 2-(3-methyl-2-oxoquinoxalin-
1(2H)-yl)-N-(4-(substituted)phenyl)-acetamides were designed
and synthesized starting with ortho-phenylenediamine by its
reaction with sodium pyruvate to afford 3-methylquinoxalin-
2(1H)-one which underwent different reactions following the
reported procedures17–26 to afford ethyl ester (1), acid hydra-
zide (2), 5-sulphanyl-oxadiazole (3), 5-phenyl-oxadiazole (4a–
c), pyrazole (5), acetyl (6), semicarbazide (7a–c), thiosemicarba-
zide (8a–c), Schiff’s bases (9a–e), triazole (10), S-alkyl (12a–f), S-
acetic acid (13), S-alkyl acetate (14a–g) and thioester (15a–c)
derivatives in order to explore the inﬂuence of incorporating
these groups on the anticonvulsant activity.
The data obtained from the biological screening of the syn-
thesized compounds revealed that; the incorporation of
Schiff’s bases (compound 9c), thiosemicarbazide (compound
8c), semicarbazide (compounds 7b and 7c) and 5-benzylsul-
phanyloxadiazole (compound 12f) moieties exhibited the high-
est anticonvulsant potency in comparing to Phenobarbital
sodium as the reference drug (Table 1).
2. Chemistry
The sequence of reactions followed in the syntheses of the tar-
get compounds is illustrated in Schemes 1–3.
A new series of 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-
(4-(substituted)phenyl)acetamides were designed and synthe-
sized starting with ortho-phenylenediamine by its reaction with
sodium pyruvate to afford 3-methylquinoxalin-2(1H)-one, fol-
lowing the reported procedures,22–26 which was then treated
with alcoholic potassium hydroxide to afford the correspond-
ing potassium salt.13 Heating of the obtained potassium salt
with ethyl-4-(2-chloroacetamido)-benzoate afforded the corre-
sponding ethyl ester (1). The reaction of (1) with hydrazine
hydrate afforded the intermediate compound N-(4-(hydrazine-
carbonyl)phenyl)-2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acet-
amide (2) which underwent cyclization by reﬂuxing with
carbon disulﬁde in the presence of alcoholic potassium hydrox-
ide followed by acidiﬁcation with hydrochloric acid to give the
corresponding 5-sulfanyloxadiazole (3) (Scheme 1).
Table 1 Anticonvulsant activity of the chosen compounds.
Test comp. Dose mg/kg Protection ED50 mg/kg ED50 mmol/kg Relative potency
3 200
100
50
66.67
33.33
16.67
150 0.38 0.13
4a 200
100
50
66.67
50.00
16.67
100 0.23 0.21
4c 200
100
50
83.33
50.00
33.33
100 0.22 0.22
5 200
100
50
83.33
50.00
16.67
75 0.18 0.27
7a 200
100
50
66.67
33.33
16.67
150 0.31 0.16
7b 200
100
50
83.33
50.00
33.33
75 0.16 0.30
7c 200
100
50
100.00
83.33
33.33
75 0.16 0.30
8a 200
100
50
66.67
33.33
16.67
100 0.23 0.21
8c 200
100
50
83.33
50.00
16.67
75 0.15 0.32
9b 200
100
50
100.00
50.00
33.33
100 0.22 0.22
9c 200
100
50
100.00
66.67
33.33
75 0.15 0.33
9d 200
100
50
66.67
33.33
16.67
150 0.32 0.15
12b 200
100
50
83.33
50.00
33.33
75 0.18 0.27
12d 200
100
50
100.00
50.00
33.33
75 0.17 0.29
12f 200
100
50
83.33
50.00
16.67
75 0.16 0.30
14a 200
100
50
50.00
16.67
16.67
200 0.43 0.11
14e 200
100
50
50.00
33.33
16.67
200 0.39 0.13
14g 200
100
50
50.00
33.33
16.67
150 0.30 0.16
15a 200
100
50
66.67
33.33
16.67
150 0.30 0.16
15b 200
100
50
83.33
50.00
16.67
150 0.28 0.18
Ph. 25
12.5
6.25
16.67 12.5 0.049 1.00
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104 M.-K. Ibrahim et al.Cyclization of the acid hydrazide (2) with the appropriate 4-
substituted benzoic acids and/or acetyl acetone afforded the
corresponding 5-phenyloxadiazole (4a–c) and pyrazole (5)
derivatives respectively. The reaction of 2 with acetic anhy-
dride, the appropriate isocyanates and/or isothiocyanates
afforded the corresponding acetyl (6), semicarbazide (7a–c),
and thiosemicarbazide (8a–c) derivatives respectively. Conden-
sation of the acid hydrazide derivative (2) with certain
aromatic aldehydes yielded the corresponding Schiff’s bases
(9a–e) (Scheme 2).
Reaction of 5-sulfanyloxadiazole derivative (3) with hydra-
zine hydrate yielded the corresponding triazole derivative (10).
The treatment of 5-sulfanyloxadiazole derivative (3) with
alcoholic potassium hydroxide resulted in the corresponding
S-potassium salt (11) which was then reacted with alkyl
bromides, 2-chloroacetic acid, alkyl-2-chloroacetates and/or
4-substitutedbenzoylchlorides to give the corresponding
S-alkyl (12a–f), S-acetic acid (13), S-alkyl acetate (14a–g) and
thioester (15a–c) derivatives respectively (Scheme 3).
2.1. Experimental
All melting points were carried out by open capillary method
on a Gallen kamp melting point apparatus at the faculty of
pharmacy, Al-Azhar University and were uncorrected. The
infrared spectra were recorded on pye Unicam SP 1000 IR
spectrophotometer at the Pharmaceutical analytical Unit, Fac-
ulty of Pharmacy, Al-Azhar University using potassium bro-
mide disc technique. Proton magnetic resonance 1H NMR
spectra were recorded on a jeol 400 MHZ-NMR spectrometer
at the Microanalytical Center, Asuit University. TMS was
used as internal standard and chemical shifts were measured
in d scale (ppm). The mass spectra were recorded on Varian
MAT 311-A (70 eV) at the Regional Center for Mycology
and Biotechnology, Al-Azhar University. Elemental analyses(C, H, N) were performed on a CHN analyzer at the Regional
Center for Mycology and Biotechnology, Al-Azhar University.
All compounds were within ±0.4 of the theoretical values. The
reactions were monitored by thin-layer chromatography
(TLC) using TLC sheets precoated with UV ﬂuorescent silica
gel Merck 60 F254 plates and were visualized using UV lamp
and different solvents as mobile phases.
3-Methylquinoxalin-2(1H)-one and its potassium salt were
obtained according to the reported procedures.18,22–26
2.1.1. Ethyl-4-(2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-
acetamido)benzoate (1)
A mixture of the potassium salt of 3-methylquinoxalin-2(1H)-
one (19.80 g, 0.1 mol) and ethyl 4-(2-chloroacetamido)benzo-
ate (24.1 g, 0.01 mol) in DMF (50 ml) was heated on a
water-bath for 14 h. After cooling to room temperature, the
reaction mixture was poured onto ice-water (500 ml) and stir-
red for 30 min. The formed precipitate was ﬁltered, washed
with water and crystallized from ethanol to give white crystals
of (1).
Yield, 75%; mp: 213–214 C. Analysis for C20H19N3O4
(mw 365); Calcd.: C, 65.74; H, 5.24; N, 11.50. Found: C,
65.89; H, 5.32; N, 11.62. IR (KBr, cm1): 3278 (NH), 3050
(C–H aromatic), 2985 (C–H aliphatic), 1740 (C@@O ester),
1667 (C@@O amide), 1601 (C@@O quinoxaline).
1H NMR
(CDCl3, ppm): 1.36 (t, 3H, CH2CH3, J= 6.8 Hz), 2.61 (s,
3H, CH3-quinox.), 4.32 (q, 2H, CH2CH3, J= 6.8 Hz), 5.03
(s, 2H, CH2), 7.26–8.03 (m, 8H, Ar–H), 9.04 (s, 1H, NH),
(D2O exchangeable). MS (m/z): 365 (M
+, 5.12%), 321
(6.34%), 201 (80.12%), 173 (20.33%) 145 (100%, base beak).
2.1.2. N-(4-(Hydrazinecarbonyl)phenyl)-2-(3-methyl-2-
oxoquinoxalin-1(2H)-yl)acetamide (2)
A mixture of ester (3.65 g, 0.01 mol) and hydrazine hydrate
(10 ml, 85%) in ethanol (20 ml) was stirred well and reﬂuxed
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Scheme 2 Synthesis of compounds 4–9.
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was collected by ﬁltration, washed with water and recrystal-
lized from ethanol.
Yield, 74%; mp: 295–297 C. Analysis for C18H17N5O3
(mw 351); Calcd.: C, 61.53; H, 4.88; N, 19.93. Found: C,
61.84; H, 4.80; N, 20.32. IR (KBr, cm1): 3342, 3300 (NH–
NH2), 3250 (NH), 3040 (C–H aromatic), 2975 (C–H aliphatic),
1672 (C@@ONHNH2), 1626 (C@@O amide), 1600 (C@@O qui-
nox.). 1H NMR (DMSO-d6, ppm): 2.50 (s, 3H, CH3,) 4.44
(s, 2H, NH2) (D2O exchangeable), 5.14 (s, 2H, CH2), 7.36–
7.80 (m, 8H, Ar–H), 9.63 (s, 1H, NH–NH2), (D2O exchange-
able), 10.63 (s, 1H, NH-phenyl) (D2O exchangeable). MS (m/
z): 351(M+, 2.01%), 320 (7.23%), 201 (20.43%), 159
(3.25%), 145 (96.20%), 131 (13.57%), 119 (100%, base beak).2.1.3. N-(4-(5-Salfanyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(3-
methyl-2-oxoquinoxalin-1(2H)-yl)-acetamide (3)
Compound (2) (3.51 g, 0.01 mol) was dissolved in a solution of
potassium hydroxide (0.56 g, 0.01 mol) in ethanol (40 ml) and
water (4 ml). Carbon disulﬁde (3 ml) was then added while stir-
ring and the reaction mixture was reﬂuxed for 24 h. The reac-
tion mixture was concentrated, cooled to room temperature
and acidiﬁed with diluted hydrochloric acid. The obtained pre-
cipitate was ﬁltered, washed with water and recrystallized from
ethanol to give compound (3).
Yield, 71%; mp: 305–307 C. Analysis for C19H15N5O3S
(mw 393); Calcd.: C, 58.01; H, 3.84; N, 17.80. Found: C,
58.14; H, 4.11; N, 17.92. IR (KBr, cm1): 3264 (NH), 3100
(C–H aromatic), 2940 (C–H aliphatic), 2590 (SH), 1649
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106 M.-K. Ibrahim et al.(C@@O amide), 1611 (C@@O quinox.).
1H NMR (DMSO-d6,
ppm): 2.49 (s, 3H, CH3), 5.15 (s, 2H, CH2), 7.34–7.93 (m,
8H, Ar–H), 10.84 (s, 1H, NH), (D2O exchangeable), 14.16 (s,
1H, SH) (D2O exchangeable). MS (m/z): 393 (M
+, 6.50%),
281 (5.22%), 215 (8.20%), 200 (53.19%), 174 (15.64%), 145
(100%, base beak).
2.1.4. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(5-(4-
substitutedphenyl)-1,3,4-oxadiazol-2-yl)phenyl)-acetamide
(4a–c)
2.1.4.1. General method. A mixture of equimolar quantities of
the acid hydrazide (2) (0.70 g, 0.002 mol) and the appropriate
4-(un) substituted benzoic acid namely, benzoic acid, 4-chloro-
benzoic acid and/or 4-ﬂourobenzoic acid (0.002 mol) in phos-
phorous oxychloride (10 ml) was heated under reﬂux at
110C for 6 h. The reaction mixture was cooled to room tem-
perature, poured carefully onto an ice-water (300 ml), and then
neutralized with solid sodium bicarbonate. The formed precip-
itate, after standing for 1 h, was ﬁltered, washed with water,
dried and crystallized from ethanol to afford compounds
(4a–c), respectively.2.1.4.2. Compound 4a. Yield, 60%; mp: 260–262 C. Analysis
for C25H19N5O3 (mw 437); Calcd.: C, 68.64; H, 4.38; N,
16.01. Found: C, 68.88; H, 4.44; N, 16.14. IR (KBr, cm1):
3240 (NH), 3053 (C–H aromatic), 2923 (C–H aliphatic),
1651 (C@@O amide), 1611 (C@@O quinox.). MS (m/z): 437
(M+, 2.13%), 377 (2.02%), 236 (5.32%), 201 (27.82%), 173
(5.48%), 145 (100% base beak), 105 (75.70%).
2.1.4.3. Compound 4b. Yield, 65%; mp: 263–265 C. Analysis
for C25H18ClN5O3 (mw 472); Calcd.: C, 63.63; H, 3.84; N,
14.84. Found: C, 64.02; H, 3.99; N, 14.11. IR (KBr, cm1):
3273 (NH), 3067 (C–H aromatic), 2940 (C–H aliphatic),
1666 (C@@O amide), 1599 (C@@O quinox.). MS (m/z): 473
(M++2, 0.55%), 472 (M+, 1.40%), 201 (25.12%), 145
(49.32%), 139 (100% base beak), 111 (77.930%), 74 (74.78%).
2.1.4.4. Compound 4c. Yield, 70%; mp: 245–247 C. Analysis
for C25H18FN5O3 (mw 455); Calcd.: C, 65.93; H, 3.98; N,
15.38. Found: C, 66.08; H, 4.12; N, 15.49. IR (KBr, cm1):
3275 (NH), 3079 (C–H aromatic), 2944 (C–H aliphatic),
1647 (C@@O amide), 1609 (C@@O quinox.).
1H NMR (CDCl3,
Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)phenyl) 107ppm): 2.49 (s, 3H, CH3), 5.17 (s, 2H, CH2), 7.35–8.15 (m, 12H,
Ar–H), 10.91 (s, 1H, NH), (D2O exchangeable).
2.1.5. N-(4-(3,5-Dimethyl-1H-pyrazol-1-ylcarbonyl)phenyl)-2-
(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetamide (5)
Acetylacetone (1.00 g, 0.01 mol) was added to a solution of
compound (2) (3.51 g, 0.01 mol) in dioxan (20 ml) and a few
drops of TEA. The reaction mixture was reﬂuxed for 4 h, con-
centrated, cooled to room temperature and the formed precip-
itate was ﬁltered and crystallized from ethanol to give
compound (5).
Yield, 65%; mp: 150–151 C. Analysis for C23H21N5O3
(mw 415); Calcd.: C, 66.49; H, 5.09; N, 16.86. Found: C,
66.63; H, 5.23; N, 17.08. IR (KBr, cm1): 3253 (NH), 3052
(C–H aromatic), 2940 (C–H aliphatic), 1663 (2C@@O over-
lapped), 1608 (C@@O quinox.). MS (m/z): 415 (M
+, 1.17%),
201 (4.61%), 186 (5.39%), 159 (7.11%), 145 (100% base beak),
118 (90.34%).
2.1.6. N-(4-(2-Acetylhydrazinecarbonyl)phenyl)-2-(3-methyl-
2-oxoquinoxalin-1(2H)-yl)acetamide (6)
Compound (2) (0.70 g, 0.002 mol) was reﬂuxed with acetic
anhydride (5 ml) for 1 h. The reaction mixture was allowed
to attain room temperature, and then poured carefully onto
ice-water (100 ml). The formed precipitate was ﬁltered and
crystallized from ethanol to give compound (6).
Yield, 65%; mp: 258–259 C. Analysis for C20H19N5O4
(mw 393); Calcd.: C, 61.06; H, 4.87; N, 17.80. Found: C,
61.14; H, 4.98; N, 17.93. IR (KBr, cm1): 3319, 3270, 3209
(NH2, 2NH), 3040 (C–H aromatic), 2947 (C–H aliphatic),
1710 (C@@O acetyl), 1664 (2C@@ONH overlapped), 1607
(C@@O quinox.). MS (m/z): 393 (M
+, 2.10%), 375 (5.02%),
320 (15.11%), 201 (100% base beak), 173 (45.70%), 161
(20.11%), 131 (22.33%), 119 (91.35%), 103 (25.71%), 91
(40.22%).
2.1.7. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(4-
substitutedsemicarbazidecarbonyl)phenyl)-acetamide (7a–c)
2.1.7.1. General method. A mixture of the acid hydrazide (2)
(0.70 g, 0.002 mol) and the appropriate isocyanate namely n-
hexyl, cyclohexyl and/or phenylisocyanate (0.015 mol) was re-
ﬂuxed in ethanol (25 ml) for 12 h. the reaction mixture was
cooled and the formed solid was ﬁltered and recrystallized
from ethanol to give compounds (7a–c) respectively.
2.1.7.2. Compound 7a. Yield, 61%; mp: 160–2 C. Analysis for
C25H30N6O4 (mw 478); Calcd.: C, 62.75; H, 6.32; N, 17.56.
Found: C, 62.89; H, 6.51; N, 17.68. IR (KBr, cm1): 3297,
3126 (4NH overlapped), 3060 (C–H aromatic), 2936 (C–H ali-
phatic), 1674 (3C@@O overlapped), 1605 (C@@O quinox.).
2.1.7.3. Compound 7b. Yield, 74%; mp: 227–229 C. Analysis
for C25H28N6O4 (mw 476); Calcd.: C, 63.01; H, 5.92; N,
17.64. Found: C, 63.19; H, 6.13; N, 17.91. IR (KBr, cm1):
3307, 3110 (4NH overlapped), 3058 (C–H aromatic), 2932
(C–H aliphatic), 1655 (3C@@O overlapped), 1605 (C@@O qui-
nox.). 1H NMR (DMSO-d6, d, ppm): 1.07–1.92 (m, 10H,
cyclohexyl), 2.52 (s, 3H, CH3), 3.54 (m, 1H, cyclohexyl), 5.17
(s, 2H, CH2), 6.28 (s, 1H, NH-cyclohexyl) (D2O exchange-
able), 6.30 (s, 1H, NHCONH-cyclohexyl) (D2O exchangeable),7.36–7.88 (m, 8H, Ar–H), 10.02 (s, 1H, NH-phenyl) (D2O
exchangeable), 10.76 (s,1H, NHNHCONH-cyclohexyl) (D2O
exchangeable).
2.1.7.4. Compound 7c. Yield, 75%; mp: 181–183 C. Analysis
for C25H22N6O4 (mw 470); Calcd.: C, 63.82; H, 4.71; N,
17.86. Found: C, 64.08; H, 4.93; N, 17.97. IR (KBr, cm1):
3308, 3203, 3133 (4NH overlapped), 3069 (C–H aromatic),
2941 (C–H aliphatic), 1653 (3C@@O overlapped), 1605 (C@@O
quinox.). MS (m/z): 470 (M+, 13.83%), 120 (25.90%), 92
(92.70%), 77 (51.50%), 65 (100% base beak).
2.1.8. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(4-
substitutedthiosemicarbazidecarbonyl)-phenyl)acetamide (8a–c)
2.1.8.1. General method. A mixture of the acid hydrazide (2)
(0.70 g, 0.002 mol) and the appropriate isothiocyanate namely
ethyl, allyl and/or phenylisothiocyanate (0.015 mol) was re-
ﬂuxed in ethanol (25 ml) for 12 h. the reaction mixture was
cooled and the formed solid was ﬁltered and recrystallized
from ethanol to give compounds (8a–c) respectively.
2.1.8.2. Compound 8a. Yield, 80%; mp: 205–207 C. Analysis
for C21H22N6O3S (mw 438); Calcd.: C, 57.52; H, 5.06; N,
19.17. Found: C, 57.73; H, 5.17; N, 19.42. IR (KBr, cm1):
3285, 3114 (4NH overlapped), 3052 (C–H aromatic), 2984
(C–H aliphatic), 1652 (2C@@O amide), 1608 (C@@O quinox.),
1251 (C@@S). MS (m/z): 437 (M
+1, 3.73%), 359 (2.97%),
295 (3.79%), 201 (6.02%), 172 (7.48), 146 (18.50%), 120
(23.36%), 118 (94.11%), 90 (68.72%), 77 (21.59%), 63
(40.31%), 51 (100%, base beak).
2.1.8.3. Compound 8b. Yield, 72%; mp: 242–244 C. Analysis
for C22H22N6O3S (mw 450); Calcd.: C, 58.65; H, 4.92; N,
18.65. Found: C, 58.82; H, 5.08; N, 18.89. IR (KBr, cm1):
3278, 3129 (4NH overlapped), 3053 (C–H aromatic), 2926
(C–H aliphatic), 1660 (2C@@O amide), 1608 (C@@O quinox.),
1264 (C@@S).
2.1.8.4. Compound 8c. Yield, 75%; mp: 230–232 C. Analysis
for C25H22N6O3S (mw 486); Calcd.: C, 61.71; H, 4.56; N,
17.27. Found: C, 61.86; H, 4.83; N, 17.43. IR (KBr, cm1):
3228, 3125 (4NH overlapped), 3050 (C–H aromatic), 2970
(C–H aliphatic), 1649 (2C@@O amide), 1604 (C@@O quinox.),
1246 (C@@S).
1H NMR (DMSO-d6, d, ppm): 2.49 (s, 3H,
CH3), 5.17 (s, 2H, SCH2), 6.98–7.89 (m, 13H, Ar–H), 9.61
(s, 1H, C@@SNHNH) (D2O exchangeable), 10.44 (s, 1H,
C@@SNH-Ph) (D2O exchangeable), 10.66 (s, 1H, C@@ONHNH)
(D2O exchangeable), 10.88 (s, 1H, C@@ONH-Ph) (D2O
exchangeable).
2.1.9. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(2-
substitutedbenzylidenehydrazinecarbonyl)-phenyl)acetamide
(9a–d)
2.1.9.1. General method. Equimolar amounts of (2) (0.70 g,
0.002 mol) and the appropriate aromatic aldehyde namely,
4-chlorobenzaldehyde, 4-ﬂourobenzaldehyde, 2,4-dichloro-
benzaldehyde, 4-methoxybenzaldehyde, and/or 4-dimethyl-
aminobenzaldehyde (0.002 mol) were reﬂuxed in glacial
acetic acid (25 ml) for 3 h. The mixture was cooled and the
formed solid was ﬁltered and crystallized from ethanol to
afford 9a–d, respectively.
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for C25H20ClN5O3 (mw 474); Calcd.: C, 63.36; H, 4.25; N,
14.78. Found: C, 63.48; H, 4.33; N, 14.93. IR (KBr, cm1):
3275, 3202 (2NH), 3071 (C–H aromatic), 2950 (C–H aliphatic),
1665 (2C@@O overlapped), 1612 (C@@O quinox.). MS (m/z): 475
(M++1, 0.65%), 474 (M+, 2.02%), 336 (5.13%), 173
(12.32%), 145 (100% base beak).
2.1.9.3. Compound 9b. Yield, 85%; mp: 280–282 C. Analysis
for C25H20FN5O3 (mw 457); Calcd.: C, 65.64; H, 4.41; N,
15.31. Found: C, 65.59; H, 4.63; N, 15.66. IR (KBr, cm1):
3275, 3206 (2NH), 3048 (C–H aromatic), 2940 (C–H aliphatic),
1658 (2C@@O overlapped), 1608 (C@@O quinox.).
1H NMR
(DMSO-d6, d, ppm): 2.51 (s, 3H, CH3,), 5.17 (s, 2H, CH2),
7.26–8.71 (m, 13H, Ar–H, N@@CH overlapped with aromatic
protons), 10.79 (s, 1H, NH-phenyl) (D2O exchangeable),
11.75 (s, 1H, N@@NHCO) (D2O exchangeable).
2.1.9.4. Compound 9c. Yield, 80%; mp: 201–203 C. Analysis
for C25H19Cl2N5O3 (mw 508); Calcd.: C, 59.07; H, 3.77; N,
13.78. Found: C, 59.24; H, 3.62; N, 13.92. MS (m/z): 511
(M++3, 0.54%), 509 (M++1, 1.42%), 508 (M+, 2.22%),
388 (2.03%), 200 (7.14%), 159 (34.86%), 131 (20.02%), 118
(60.32), 104 (30.23), 90 (25.44%), 74 (25.21%), 63 (40.15%),
50 (100% base beak).
2.1.9.5. Compound 9d. Yield, 81%; mp: 330–332 C.
Analysis for C26H23N5O3 (mw 469); Calcd.: C, 66.51; H,
4.94; N, 14.92. Found: C, 66.87; H, 5.30; N, 15.23. MS
(m/z): 469 (M+, 2.03%), 320 (1.17%), 200 (7.14%), 145
(53.09%), 131 (14.42%), 119 (100% base beak), 104 (22.63),
91 (97.03%).
2.1.9.6. Compound 9e. Yield, 67%; mp: 273–275 C. Analysis
for C27H26N6O3 (mw 482); Calcd.: C, 67.21; H, 5.43; N,
17.42. Found: C, 67.837 H, 5.58; N, 17.37. IR (KBr, cm1):
3259, 3185 (2NH), 3049 (C–H aromatic), 2955 (C–H aliphatic),
1658 (2C@@O overlapped), 1608 (C@@O quinox.).2.1.10. N-(4-(4-Amino-5-sulfanyl-4H-1,2,4-triazol-3-
yl)phenyl)-2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetamide
(10)
Compound (3) (3.93 g, 0.01 mol) was dissolved in ethanol
(50 ml), hydrazine hydrate (10 ml, 85%) was added and the
reaction mixture was heated under reﬂux on an oil-bath at
110C for 8 h. The reaction mixture was evaporated to dryness
under reduced pressure; the obtained solid was dissolved in
water (300 ml) and acidiﬁed with conc. HCl to pH 1.00. The
precipitate was ﬁltered, washed with water and crystallized
from chloroform/ethanol (2/1) mixture to afford the desired
compound (9).
Yield, 71%; mp: 222–224 C. Analysis for C19H17N7O2S
(mw 407); Calcd.: C, 56.01; H, 4.21; N, 24.06. Found: C,
56.12; H, 4.29; N, 24.18. IR (KBr, cm1): 3270, 3212
(NH2, NH), 3023 (C–H aromatic), 2928 (C–H aliphatic),
2625 (SH), 1639 (C@@O amide), 1603 (C@@O quinox.). MS
(m/z): 406 (M+1, 1.10%), 390 (1.05%), 259 (1.15), 201
(2.31%), 173 (3.06%), 146 (35.31%), 130 (20.43%), 116
(15.11%), 100 (17.98), 85 (18.00%), 73 (16.30%), 58 (100%
base beak).2.1.11. Potassium salt of N-(4-(5-salfanyl-1,3,4-oxadiazol-2-
yl)phenyl)-2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-acetamide
(11)
A mixture of (4) (3.93 g, 0.01 mol) and potassium hydroxide
(0.56 g, 0.01 mol) in absolute ethanol (20 ml) was reﬂuxed
for 0.5 h. Upon cooling to room temperature, a yellow precip-
itate was obtained which was collected and washed with
diethyl ether to afford the corresponding potassium salt (11).
Yield, 95%; mp: >300 C. Analysis for C19H14KN5O3S
(mw 431); Calcd.: C, 52.88; H, 3.27; N, 16.23. Found: C,
52.50; H, 3.67; N, 16.55.
2.1.12. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(5-
(substitutedsulfanyl)-1,3,4-oxadiazol-2-yl)-phenyl)acetamide
(12a–f)
2.1.12.1. General method. A mixture of the potassium salt (11),
(0.86 g, 0.002 mol) and the appropriate alkyl bromide, namely
methyl, ethyl, propyl, butyl, allyl and/or benzyl bromide
(0.002 mol) in DMF (20 ml) was heated on a water-bath for
2 h. After cooling to room temperature, the reaction mixture
was poured onto ice-water (150 ml) while stirring. The formed
precipitate was ﬁltered, washed with water and crystallized
from ethanol to yield the corresponding compounds (12a–f)
respectively.
2.1.12.2. Compound 12a. Yield, 77%; mp: 264–266 C. Analysis
for C20H17N5O3S (mw 407); Calcd.: C, 58.96; H, 4.21; N,
17.19. Found: C, 59.28; H, 4.38; N, 17.31. IR (KBr, cm1):
3274 (NH), 3055 (C–H aromatic), 2933 (C–H aliphatic),
1660 (C@@O amide), 1602 (C@@O quinox.). MS (m/z): 407
(M+, 2.02%), 371 (2.55%), 339 (2.28%), 286 (1.98%), 258
(2.13%), 243 (2.22%), 201 (3.71%), 186 (2.82%), 145 (100%,
base beak), 131 (18.17%), 119 (58.12%), 90 (28.78%), 75
(74.70%), 58 (74.50%).
2.1.12.3. Compound 12b. Yield, 76%; mp: 272–274 C. Analysis
for C21H19N5O3S (mw 421); Calcd.: C, 59.84; H, 4.54; N,
16.62. Found: C, 59.89; H, 4.61; N, 16.63. IR (KBr, cm1):
3266 (NH), 3080 (C–H aromatic), 2979 (C–H aliphatic),
1652 (C@@O amide), 1607 (C@@O quinox.).
2.1.12.4. Compound 12c. Yield, 70%; mp: 267–269 C. Analysis
for C22H21N5O3S (mw 435); Calcd.: C, 60.67; H, 4.86; N,
16.08. Found: C, 60.85; H, 4.97; N, 16.16. MS (m/z): 435
(M+, 1.19%), 345 (1.02%), 234 (5.20%), 201 (15.01%), 173
(10.03%), 145 (100%, base beak), 131(25.11%), 118 (40.32%).
2.1.12.5. Compound 12d. Yield, 73%; mp: 280–282 C. Analysis
for C23H23N5O3S (mw 449); Calcd.: C, 61.45; H, 5.16; N,
15.58. Found: C, 61.59; H, 5.39; N, 15.69. IR (KBr, cm1):
3282 (NH), 3055 (C–H aromatic), 2990 (C–H aliphatic),
1670 (C@@O amide), 1606 (C@@O quinox.).
1H NMR
(DMSO-d6, d, ppm): 0.95 (t, 3H, CH2CH3, J= 8 Hz), 1.47
(m, 2H, CH2CH2 CH2CH3, J= 8 Hz), 1.79 (m, 2H,
CH2CH2CH2CH3, J= 7.2 Hz), 2.66 (s, 3H, CH3 of quinox.),
3.28 (t, 2H, CH2CH2CH2CH3, J= 7.2 Hz), 5.05 (s, 2H,
CH2CO), 7.27–7.92 (m, 8H, Ar–H), 9.06 (s, 1H, NH) (D2O
exchangeable).
2.1.12.6. Compound 12e. Yield, 75%; mp: 290–292 C. Analysis
for C22H19N5O3S (mw 433); Calcd.: C, 60.96; H, 4.42; N,
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2.73%), 396 (3.30%), 363 (4.11%), 296 (2.48%), 232 (4.76),
218 (2.71), 186 (2.84%), 173 (5.14%), 158 (4.88), 145 (100%
base beak), 131 (16.49%), 103 (9.13%), 91 (35.16), 76
(28.34%), 63 (22.19%), 51 (35.68%).
2.1.12.7. Compound 12f. Yield, 67%; mp: 194–196 C. Analysis
for C26H21N5O3S (mw 483); Calcd.: C, 64.58; H, 4.38; N,
14.48. Found: C, 64.45; H, 4.45; N, 14.54. IR (KBr, cm1):
3258 (NH), 3055 (C–H aromatic), 2933 (C–H aliphatic),
1659 (C@@O amide), 1608 (C@@O quinox.).
1H NMR (CDCl3,
d, ppm): 2.65 (s, 3H, CH3), 4.72 (s, 2H, PhCH2), 5.03 (s, 2H,
COCH2), 7.23–8.09 (m, 13H, Ar–H), 9.07 (s, 1H, NH), (D2O
exchangeable).
2.1.13. 2-(5-(4-(2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-
acetamido)phenyl)-1,3,4-oxadiazol-2-yl-sulfanyl)acetic acid
(13)
A mixture of the potassium salt (11), (0.86 g, 0.002 mol), 2-
chloroacetic acid (0.19 g, 0.002 mol) in DMF (20 ml) was
heated on a water-bath for 2 h. After cooling to room temper-
ature, the reaction mixture was poured onto ice-water (150 ml)
while stirring. The formed precipitate was ﬁltered, washed with
water, and crystallized from ethanol.
Yield, 67%; mp: 194–196 C. Analysis for C21H17N5O5S
(mw 451); Calcd.: C, 55.87; H, 3.80; N, 15.51. Found: C,
55.98; H, 3.93; N, 15.63. MS (m/z): 451 (M+, 11.22%), 400
(10.72%), 330 (11.32%), 271 (23.51%), 242 (14.73%), 201
(33.23), 173 (23.76%), 153 (21.62), 145 (100%, base beak),
120 (61.50%), 111 (62.90%), 102 (56.97%), 92 (54.85), 75
(75.68), 63 (57.65), 51 (81.20).
2.1.14. Alkyl-2-(5-(4-(2-(3-methyl-2-oxoquinoxalin-1(2H)-
yl)-acetamido)phenyl)-1,3,4-oxadiazol-2-ylsalfanyl)acetate
(14a–g)
2.1.14.1. General method. A mixture of the potassium salt (11),
(0.86 g, 0.002 mol) and the appropriate alkyl chloroacetate,
namely methyl, ethyl, propyl, isopropyl, butyl, isobutyl and/
or ter.butyl chloroacetate (0.012 mol) in DMF (20 ml) was
heated on a water-bath for 2 h. After cooling to room temper-
ature, the reaction mixture was poured onto an ice-water
(150 ml) while stirring. The formed precipitate was ﬁltered,
washed with water and crystallized from ethanol to afford
the corresponding ester derivatives (13a–g) respectively.
2.1.14.2. Compound 14a. Yield, 71%; mp: 226–228 C. Analysis
for C22H19N5O5S (mw 465); Calcd.: C, 56.77; H, 4.11; N,
15.05. Found: C, 56.89; H, 4.24; N, 15.13. IR (KBr, cm1):
3273 (NH), 3049 (C–H aromatic), 2964 (C–H aliphatic),
1733 (C@@O ester), 1659 (C@@O amide), 1610 (C@@O quinox.).
1H NMR (DMSO-d6, d, ppm): 2.59 (s, 3H, CH3), 2.64 (s,
3H, OCH3), 2.73 (s, 2H, SCH2), 5.01 (s, 2H, CH2C@@O),
7.24–7.90 (m, 8H, Ar–H), 9.00 (s, 1H, NH) (D2O
exchangeable).
2.1.14.3. Compound 14b. Yield, 72%; mp: 194–196 C. Analysis
for C23H21N5O5S (mw 479); Calcd.: C, 57.61; H, 4.41; N,
14.61. Found: C, 57.67; H, 4.52; N, 14.82. IR (KBr, cm1):
3282 (NH), 3089 (C–H aromatic), 2984 (C–H aliphatic),
1721 (C@@O ester), 1651 (C@@O amide), 1610 (C@@O quinox.).
1H NMR (DMSO-d6, d, ppm): 1.24 (t, 3H, CH2CH3), 2.63(s, 3H, CH3), 4.06 (q, 2H, CH2CH3), 4.21 (s, 2H, SCH2),
5.01 (s, 2H, CH2C@@O), 7.24–7.99 (m, 8H, Ar–H), 9.01 (s,
1H, NH) (D2O exchangeable).
2.1.14.4. Compound 14c. Yield, 70%; mp: 190–192 C. Analysis
for C24H23N5O5S (mw 493); Calcd.: C, 58.41; H, 4.70; N, 14.19.
Found: C, 58.52; H, 4.81; N, 14.59. IR (KBr, cm1): 3293 (NH),
3057 (C–H aromatic), 2962 (C–H aliphatic), 1720 (C@@O ester),
1654 (C@@O amide), 1608 (C@@O quinox.).
1HNMR (DMSO-d6,
d, ppm): 0.93 (t, 3H,CH2CH3), 1.68 (m, 2H,CH2CH2CH3), 2.64
(s, 3H, CH3 of quinox.), 4.12 (t, 2H, CH2CH2CH3), 4.27 (s, 2H,
SCH2), 5.06 (s, 2H, CH2CO), 7.27–7.85 (m, 8H, Ar–H), 9.14 (s,
1H, NH) (D2O exchangeable).
2.1.14.5. Compound 14d. Yield, 71%; mp: 123–124 C. Analysis
for C24H23N5O5S (mw 493); Calcd.: C, 58.41; H, 4.70; N,
14.19. Found: C, 58.54; H, 4.79; N, 14.58. MS (m/z): 494
(M++1, 2.13%), 421 (1.34%), 393 (6.97%), 201 (50.19%),
173 (20.70%), 145 (100%, base beak), 118 (70.37%), 91
(55.10%).
2.1.14.6. Compound 14e. Yield, 65%; mp: 157–158 C. Analysis
for C25H25N5O5S (mw 507); Calcd.: C, 59.16; H, 4.96; N,
13.80. Found: C, 59.30; H, 5.04; N, 13.91. MS (m/z): 507
(M+, 3.06%), 391 (2.75%), 307 (3.07%), 293 (5.87%), 202
(8.80%), 201 (97.91%), 173 (27.67%), 145 (100%, base beak).
2.1.14.7. Compound 14f. Yield, 63%; mp: 164–165 C. Analysis
for C25H25N5O5S (mw 507); Calcd.: C, 59.16; H, 4.96; N,
13.80. Found: C, 59.38; H, 5.10; N, 13.90. IR (KBr, cm1):
3301 (NH), 3063 (C–H aromatic), 2957 (C–H aliphatic),
1721 (C@@O ester), 1643 (C@@O amide), 1611 (C@@O quinox.).
1H NMR (DMSO-d6, d, ppm): 0.89 (d, 6H, CH(CH3)2), 1.93
(m, 1H, CH(CH3)2), 2.57 (s, 3H, CH3 of quinox.), 3.92
(d, 2H, OCH2CH), 4.07 (s, 2H, SCH2), 5.03 (s, 2H, CH2CO),
7.24–7.81 (m, 8H, Ar–H), 9.12 (s, 1H, NH) (D2O
exchangeable).
2.1.14.8. Compound 14g. Yield, 60%; mp: 118–120 C. Analysis
for C25H25N5O5S (mw 507); Calcd.: C, 59.16; H, 4.96; N,
13.80. Found: C, 59.39; H, 5.12; N, 13.91. IR (KBr, cm1):
3291 (NH), 3067 (C–H aromatic), 2979 (C–H aliphatic),
1723 (C@@O ester), 1660 (C@@O amide), 1608 (C@@O quinox.).
1H NMR (DMSO-d6, d, ppm): 1.43 (s, 9H, C(CH3)3), 2.57
(s, 3H, CH3 of quinox.), 4.02 (s, 2H, SCH2), 5.02 (s, 2H,
CH2CO), 7.07–8.12 (m, 8H, Ar–H), 9.14 (s, 1H, NH) (D2O
exchangeable).
2.1.15. 2-(3-Methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(5-(4-
(un)substitutedbenzoylsulfanyl)-1,3,4-oxadiazol-2-yl)-
phenyl)acetamide (15a–c)
2.1.15.1. General method. A mixture of the potassium salt (11),
(0.86 g, 0.002 mol) and the appropriate 4-(un)substituted ben-
zoyl chloride, namely benzoyl chloride, 4-chlorobenzoyl chlo-
ride and/or 4-ﬂourobenzoyl chloride (0.002 mol) in DMF
(20 ml) was heated on a water-bath for 1 h. After cooling to
room temperature, the reaction mixture was poured onto ice-
water (150 ml) while stirring. The formed precipitate was
ﬁltered, washed with water and crystallized from ethanol
to afford the corresponding thioester derivatives (15a–c)
respectively.
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for C26H19N5O4S (mw 497); Calcd.: C, 62.77; H, 3.85; N,
14.08. Found: C, 62.84; H, 4.02; N, 14.20. IR (KBr, cm1):
3261 (NH), 3049 (C–H aromatic), 2940 (C–H aliphatic),
1646 (2 C@@O overlapped), 1609 (C@@O quinox.).
1H NMR
(DMSO-d6, d, ppm): 2.55 (s, 3H, CH3), 5.13 (s, 2H, CH2),
7.33–8.11 (m, 13H, Ar–H), 9.15 (s, 1H, NH) (D2O
exchangeable).
2.1.15.3. Compound 15b. Yield, 65%; mp: 255–257 C. Analysis
for C26H18ClN5O4S (mw 531); Calcd.: C, 58.70; H, 3.41; N,
13.16. Found: C, 58.89; H, 3.30; N, 13.19. IR (KBr, cm1):
3282 (NH), 3081 (C–H aromatic), 2934 (C–H aliphatic),
1653 (2C@@O overlapped), 1606 (C@@O quinox.).
1H NMR
(DMSO-d6, d, ppm): 2.25 (s, 3H, CH3), 5.17 (s, 2H, COCH2),
7.35–8.12 (m, 12H, Ar–H), 10.9 (s, 1H, NH) (D2O
exchangeable).
2.1.15.4. Compound 15c. Yield, 64%; mp: 171–173 C. Analysis
for C26H18FN5O4S (mw 515); Calcd.: C, 60.58; H, 3.52; N,
13.59. Found: C, 60.42; H, 3.81; N, 13.67. IR (KBr, cm1):
3203 (NH), 3078 (C–H aromatic), 2999 (C–H aliphatic),
1687 (2C@@O overlapped), 1604 (C@@O quinox.). MS (m/z):
516 (M++1, 2.21%), 515 (M+, 5.11%), 362 (5.07%), 319
(5.94%), 285 (6.33%), 256 (4.97%), 233 (5.15%), 190
(5.82%), 111 (17.27%), 91 (23.56%), 65 (20.93%), 57 (100%,
base beak).
3. Anticonvulsant Screening
In the present study, 20 compounds of the newly synthesized
quinoxaline derivatives were selected to be screened in vivo
for their anticonvulsant activity against pentylenetetrazole-in-
duced convulsions in mice following a reported procedure.27,28
The results were compared with Phenobarbital sodium as a
standard anticonvulsant.
The animal studies were undertaken with approval from the
Ethics Committee (approval # 23PD/3/12/8R) of Al-Azhar
University, Nasr City, Cairo, Egypt. All the trials were carried
out according to the respective internationally guidelines.
Swiss albino adult male mice, weighing 20–25 g, were used as
experimental animals. They were obtained from an animal
facility (Animal house, Department of Pharmacology and
Toxicology, Faculty of Pharmacy, Al-Azhar University). Mice
were housed in stainless steel wire-ﬂoored cages without any
stressful stimuli. Animals were kept under well-ventilated con-
ditions at room temperature (25–30 C). They were fed on an
adequate standard laboratory chow (El-Nasr Co., Abou-Za-
bal, Egypt) and allowed to acclimatize with free access to food
and water for a 24 h period before testing except during the
short time when they were removed from the cages for testing.
Albino mice were randomly arranged in groups, each of 6 ani-
mals. Phenobarbital sodium (Sigma–Aldrich Chemical Co,
Milwaukee, WI, USA) was used as a reference drug for com-
parison. Pentylenetetrazole (Sigma–Aldrich Chemical Co, Mil-
waukee, WI, USA) was used to induce convulsions in the
experimental animals.
The test compounds were solublized in DMSO. Test com-
pounds were orally administered in a dose ranging from 50
to 200 mg/kg animal weight using the same dosing volume of
0.2 ml per 20 g. Pentylenetetrazole (PTZ, Sigma) was dissolvedin normal saline in 2% concentration and was given intraper-
itoneally (i.p.) in a dose of 60 mg/kg body weight (dose that
could induce convulsions in at least 80% of the animals with-
out death during the following 24 h). Phenobarbital sodium
(Sigma, USA) was dissolved in normal saline in 2% concentra-
tion and it was i.p. given in doses of 6.25, 12.5 and 25 mg/kg
using the same dosing volume. All drugs were freshly prepared
to the desired concentration just before use.
Groups of 6 mice were administered the graded doses of the
test compounds orally. Control animals received an equal vol-
ume of saline (10 ml/kg). After 1 h, the animals were subcuta-
neously injected with the convulsive dose of pentylenetetrazole
(60 mg/kg). The criterion of anticonvulsant activity is complete
protection against convulsions of any kind. Observations were
made at least 60 min after the administration of pentylenetet-
razole. Doses that gave full protection against the induced con-
vulsions and that which exhibited 50% protection in addition
to the relative potencies of the test compounds to Phenobarbi-
tal sodium were recorded.
The percentage protection per dose and the ED50 of each
compound (in mg/kg and millimole) were calculated and pre-
sented in (Table 1). Finally the relative potencies of the test
compounds compared to Phenobarbital sodium was calculated
and used for comparison among compounds under test as
shown in (Table 1).
The data presented in (Table 1) showed that: all the tested
compounds (3, 4a, 4c, 5, 7a, 7b, 7c, 8a, 8c, 9b, 9c, 9d, 12b, 12d, 12f,
14a, 14e, 14g, 15a and 15b) showed anticonvulsant activities les-
ser than that of the reference drug. Their potencies range from
0.33 to 0.11 of that of Phenobarbital sodium. Compounds 9c
and 8c showed the highest anticonvulsant activities in experi-
mental mice with anticonvulsant potency in comparing to Phe-
nobarbital sodium as the reference drug of 0.33 and 0.32
respectively. Compounds 7b, 7c and 12f exhibited the same rel-
ative potency of 0.30. Compound 2 exhibited the lowest rela-
tive potency of 0.09. The other compounds showed variable
relative potencies of 0.11–0.29. Compounds 7c, 9b, 9c and 12d
caused 100% protection in a dose of 200 mg/kg body weight,
compounds 4c, 5, 7b, 8c, 12b, 12f and 15b caused 83.33%, com-
pounds 3, 4a, 7a, 8a, 9d and 15a caused 66.67% protection while
the other compounds caused 50% protection at the same dose
(Table 1). Compounds 5, 7b, 7c, 8c, 9c, 12b, 12d and 12f caused
50% protection in a dose of 75 mg/kg body weight while the
remaining compounds showed 50% protection at higher doses.
The percent of protection per dose as well as the medium effec-
tive dose (ED50), which makes 50% protection of animals was
calculated using INSTANT 2 program (ICS, Philadelphia, PA,
USA), presented in (Table 1). In spite of all compounds exhib-
ited anticonvulsant activities lesser than that of Phenobarbital
sodium, it provided a basis for further optimization.
4. Conclusion
The data obtained from biological screening revealed that; all
the tested compounds showed anticonvulsant activities lesser
than that of Phenobarbital sodium as the reference drug. Their
potencies range from 0.33 to 0.11 of that of Phenobarbital.
Compounds 9c and 8c showed the highest anticonvulsant activ-
ities in experimental mice with anticonvulsant potency in com-
paring to Phenobarbital sodium as the reference drug of 0.33
and 0.32 respectively. Compounds 7b, 7c and 12f exhibited
Design and synthesis of some novel 2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)-N-(4-(substituted)phenyl) 111the same relative potency of 0.30. Compound 14a exhibited the
lowest relative potency of 0.11. The other compounds showed
variable relative potencies of 0.13–0.29. In spite of all com-
pounds exhibited anticonvulsant activities lesser than that of
Phenobarbital sodium, it provided a basis for further
optimization.
5. Conﬂict of interest
None.
References
1. Husain A, Rashid M, Akhter A, Mishra R, Gupta D. Design,
synthesis and pharmacological activities of novel N-1-2-(substi-
tuted phenyl)-4-oxo-1,3-thiazolan-3-yl-2,2-diphenyl-acetamides.
Int J Pharm Sci Rev Res 2010;5(2):102–6.
2. Husain A, Naseer MA, Sarafroz M. Synthesis and anticonvulsant
activity of some novel fused heterocyclic 1,2,4-triazolo-3,4-b-1,3,4-
thiadiazole derivatives. Acta Polo Pharm Drug Res 2009;66(2):
135–40.
3. Bourgeois BF. New antiepileptic drugs. Arch Neurol 1998;55:
1181–3.
4. Loring DW. Cognitive side effects of antiepileptic drugs in
children. Psychiatric Times 2005;XXII(10):1–7.
5. Husain A, Rashid M, Akhter A, Mishra R. Synthesis of new 1,2,4-
triazolo3,4-B[1,3,4]thiadiazole derivatives and their pharmacolog-
ical evaluation. J Pharm Res 2011;4(3):888–90.
6. Abu-Hashem AA, Gouda MA, Badria FA. Synthesis of some new
pyrimido20,10:2,3thiazolo[4,5-b]quinoxaline derivatives as anti-
inﬂammatory and analgesic agents. Eur J Med Chem 2010;45:
1976–81.
7. Chapman AG, Smith SE, Meldrum BS. The anticonvulsant effect
of the non-NMDA antagonists, NBQX and GYKI 52466 in mice.
Epilepsy Res 1991;2:92–6.
8. Ogita K, Yoneda Y. 6,7-Dichloroquinoxaline-2,3-dione is a
competitive antagonist speciﬁc to strychnine-insensitive 3H glycine
binding sites on the N-methyl-D-aspartate receptor complex. J
Neurochem 1990;54:699–702.
9. Jackson PF, Davenport TW, Resch JF, Lehr GS, Pullan LM.
Tricyclic quinoxalines as ligands for the strychnine-insensitive
glycine site. Bioorg Med Chem Lett 1991;1:751–6.
10. McQuaid LA, Smith EC, South KK, Mitch CH, Schoepp DD,
True RA, et al. Synthesis and excitatory amino acid pharmacol-
ogy of a series of heterocyclic-fused quinoxalinones and quinaz-
olinones. J Med Chem 1992;35:3319–24.
11. Wagle S, Adhikari AV, Kumari NS. Synthesis of some new 4-
styryltetrazolo1,5-aquinoxaline and 1-substituted-4-styryl[1,2,4]
triazolo[4,3-a]quinoxaline derivatives as potent anticonvulsants.
Eur J Med Chem 2009;44:1135–43.
12. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic
drug development. Neurotherapeutics 2007;4:18–61.13. Rogawski MA, Bazil CW. New molecular targets for antiepileptic
drugs: a2d, SV2A, and Kv7/KCNQ/M potassium channels. Curr
Neurol Neurosci Rep 2008;8(4):345–52.
14. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the
development pipeline. Epilepsy Res 2006;69:273–94.
15. Rutecki PA, Sayin U, Yang Y, Hadar E. Determinants of ictal
epilepticform patterns in the hippocampal slice. Epilepsia 2002;43:
179–83.
16. Barril X, Soliva J. Molecular modelling. Mol Model R Soc Chem
2006;2:660–81.
17. Bayoumi A, Ghiaty A, El-Morsy A, Abul-Khair H, Hassan MH,
Elmeligie S. Synthesis and evaluation of some new 1,2,4-triazol-
o(4,3-a)quinoxalin-4-5H-one derivatives as AMPA receptor antag-
onists. Bull Fac Pharm, Cairo Univ 2012;2:141–6.
18. Elhelby AA, Ayyad RR, Zayed MF. Synthesis and biological
evaluation of some novel quinoxaline derivatives as anticonvulsant
agents. Arzneimittelforschung 2011;61(7):379–81.
19. Ibrahim MK, Abdel-Rahman AA, Ayyad RRA, El-Adl K, El-
sherbeny F, Rashed M. Design and synthesis of some novel N-
phthalimide derivatives with potential anticonvulsant activity. Al-
Azhar J Pharm Sci 2010;42:305–22.
20. El-Helby AA, Ibrahim MK, Abdel-Rahman AA, Ayyad RRA,
Menshawy MA, El-Adl K. Synthesis, molecular modeling and
anticonvulsant activity of benzoxazole derivatives. Al-Azhar J
Pharm Sci 2009;40:252–70.
21. El-Adl K. Design and synthesis of some novel 2-(5-meth-
ylbenzoxazol-2-ylsalfanyl)-N-(4-substitutedphenyl)acetamide
derivatives with potential anticonvulsant activity. Al-Azhar J
Pharm Sci 2011;44:183–204.
22. Arnowski TZ, Kleinrok Z, Turski WA, Czuczwar SJ. 2,3-
dihydroxy-6-nitro-7-sulfamoylbenzo-(F)quinoxaline enhances the
protective activity of common antiepileptic drugs against maximal
electroshock-induced seizures in mice. Neuropharmacology
1993;32:895–900.
23. Varano F, Catarzi D, Colotta V, Cecchi L, Filacchioni G, Galli A.
Synthesis of a set of ethyl1-carbamoyl-3-oxo-quinoxaline-2-car-
boxylates and of their constrained analogue imidazo1,5-aquinox-
aline-1,3,4-trionesasglycine/NMDA receptor antagonists. Eur J
Med Chem 2001;36:203–9.
24. Abubshait HA. Synthesis and reactions of some novel quinoxaline
derivatives. Arab J Chem 2008;1(2):183–99.
25. Ratnadeep CV, Pramodkumar SJ. Synthesis of some new Schiff’s
bases of quinoxaline-2(1H)-one as potent anti-inﬂammatory
agents. Inter J Pharm Res Dev 2011;3(7):157–64.
26. Umarani N, Ilango K. Bridgehead nitrogen heterocyclic systems:
facile synthesis, bioactivity of some newer derivatives of 1-
substituted benzylidene hydrazinotetrazolo1,5-a-quinoxalines. Int
J Pharm Sci Rev Res 2010;2(2):24–8.
27. Loscher W, Honack D, Fassbender CP, Nolting B. The role of
technical, biological and pharmacological factors in the laboratory
evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure
models. Epilepsy Res 1991;8:171–89.
28. Vogel GH. Drug discovery and evaluation: pharmacological assays.
3rd ed. New York: Springer-Verlag; 2008 692–693.
